Back to Journals » Lung Cancer: Targets and Therapy » Volume 11

Lung Cancer: Targets and Therapy


Archive: Volume 11, 2020

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations

Yang W, Chen N, Li L, Chen X, Liu X, Zhang Y, Cui J

Lung Cancer: Targets and Therapy 2020, 11:59-71

Published Date: 7 September 2020

Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer

Noguchi S, Suminaga K, Kaki T, Kawachi H, Fukao A, Terashita S, Horikawa S, Ikeue T, Sugita T

Lung Cancer: Targets and Therapy 2020, 11:53-57

Published Date: 12 July 2020

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors

Schrock AB, Madison R, Rosenzweig M, Allen JM, Erlich RL, Wang SY, Chidiac T, Reddy VS, Riess JW, Yassa AE, Shakir A, Miller VA, Alexander BM, Venstrom J, McGregor K, Ali SM

Lung Cancer: Targets and Therapy 2020, 11:33-39

Published Date: 17 April 2020

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients

Mehta A, Saifi M, Batra U, Suryavanshi M, Gupta K

Lung Cancer: Targets and Therapy 2020, 11:19-25

Published Date: 24 February 2020

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases

Zhu VW, Nagasaka M, Kubota T, Raval K, Robinette N, Armas O, Al-Holou W, Ou SI

Lung Cancer: Targets and Therapy 2020, 11:13-18

Published Date: 14 January 2020

The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer

Cheng YY, Rath EM, Linton A, Yuen ML, Takahashi K, Lee K

Lung Cancer: Targets and Therapy 2020, 11:1-11

Published Date: 8 January 2020